Tea planter Vishal Mahindra was twice diagnosed with non-Hodgkin's lymphoma, a type of blood cancer that develops in the ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Patients must have received ≥2 previous lines of systemic therapy, be ineligible for hematopoietic SCT or CAR T-cell therapy, and have an Eastern Cooperative Oncology Group performance status of ≤2.

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter ...

Kathryn Senior reports. Chimeric antigen receptor (CAR) T-cell therapies have proved effective in several haematological cancers including B-cell acute lymphoblastic leukaemia, diffuse large B-cell ...

"In patients with follicular lymphoma, FT596 has shown comparable efficacy to the three FDA-approved CAR-T cell therapies, but with significantly reduced toxicity," Ghobadi said. "For patients ...

"In patients with follicular lymphoma, FT596 has shown comparable efficacy to the three FDA-approved CAR-T cell therapies, but with significantly reduced toxicity," Ghobadi said. "For patients ...

Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans. Nature Microbiology , 2025; DOI: 10.1038/s41564-024-01903-7 Cite This Page : ...

The asset in question, an autologous CAR-T dubbed ASP2802 aimed at CD20-positive B-cell lymphomas, had been undergoing a phase 1 trial to determine a suitable dose for further studies as well as ...

May the force not be with you: Cell migration doesn't only rely on generating force. ScienceDaily . Retrieved January 29, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250109141125.htm ...